{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:35Z","timestamp":1791520835500,"version":"4.3.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:p>\n                    Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension. The aldosterone\/plasma renin activity ratio (ARR) is routinely used as a screening test. Antihypertensive therapy can interfere with the interpretation of this parameter, but a correct washout period can be potentially harmful. We have investigated the effects of therapy with atenolol, amlodipine, doxazosin, fosinopril, and irbesartan on the ARR in a group of 230 patients with suspected primary aldosteronism. The percent change from control of ARR in patients taking amlodipine was \u221217%\u00b132; atenolol, 62%\u00b182; doxazosin, \u22125%\u00b126; fosinopril, \u221230%\u00b124; and irbesartan, \u221243%\u00b127. The ARR change induced by atenolol was significantly higher compared with that induced by all other drugs (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.0001), and the ARR change induced by irbesartan was significantly lower than that induced by doxazosin (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.0001). One of 55 patients from the group taking amlodipine (1.8%) and 4\/17 of the patients taking irbesartan (23.5%) gave a false-negative ARR (&lt;50). None of the patients of the groups taking fosinopril, doxazosin, and atenolol displayed a false-negative ARR. Doxazosin and fosinopril can be used in hypertensive patients who need to undergo aldosterone and PRA measurement for the diagnosis of primary aldosteronism; amlodipine gave a very small percentage of false-negative diagnoses. \u03b2-Blockers also do not interfere with the diagnosis of primary aldosteronism, but they can be responsible for an increased rate of false-positive ARRs. The high rate of false-negative diagnoses in patients undergoing irbesartan treatment requires confirmation in a higher number of patients.\n                  <\/jats:p>","DOI":"10.1161\/01.hyp.0000038478.59760.41","type":"journal-article","created":{"date-parts":[[2002,12,5]],"date-time":"2002-12-05T16:43:15Z","timestamp":1039106595000},"page":"897-902","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":316,"title":["Drug Effects on Aldosterone\/Plasma Renin Activity Ratio in Primary Aldosteronism"],"prefix":"10.1161","volume":"40","author":[{"given":"Paolo","family":"Mulatero","sequence":"first","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Rabbia","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Milan","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Paglieri","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Morello","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Chiandussi","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Veglio","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Experimental Oncology, Hypertension Unit, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_1_2","unstructured":"Kaplan NM. Clinical Hypertension 6th ed. Baltimore: Williams and Wilkins; 1994; 389\u2013408."},{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812173392507"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1993.tb01687.x"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"e_1_3_1_5_2","first-page":"1863","volume":"85","year":"2000","unstructured":"Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000; 85: 1863\u20131867.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_1_6_2","first-page":"2854","volume":"85","year":"2000","unstructured":"Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000; 85: 2854\u20132859.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001013"},{"key":"e_1_3_1_8_2","first-page":"1589","volume":"41","year":"1981","unstructured":"Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med. 1981; 41: 1589\u20131593.","journal-title":"Arch Intern Med"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2001.022"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045415-199907000-00012"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00060793-200106000-00004"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197212142872401"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/07435809209035402"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1981.tb11587.x"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-199707040-00003"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03349761"},{"key":"e_1_3_1_17_2","first-page":"457","volume":"82","year":"1997","unstructured":"Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab. 1997; 82: 457\u2013460.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.75.882.235"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90160-4"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90438-Q"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1987.tb00967.x"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(01)80117-7"},{"key":"e_1_3_1_23_2","first-page":"1","volume":"7","year":"1999","unstructured":"Veglio F, Rabbia F, Mengozzi G, Zocchi C, Mulatero P, Martini G, Morra di Cella S, Chiandussi L. Assessment of a threshold value of the aldosterone\/plasma renin activity ratio in the screening of primary aldosteronism. Intern Med. 1999; 7: 1\u20138.","journal-title":"Intern Med"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.6.5.717"},{"key":"e_1_3_1_25_2","first-page":"1066","volume":"86","year":"2001","unstructured":"Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, Findling JW. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab. 2001; 86: 1066\u20131071.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.7.4946"},{"key":"e_1_3_1_27_2","first-page":"3996","volume":"83","year":"1998","unstructured":"Mulatero P, Curnow KM, Aupetit-Faisant B, Foekling M, Gomez-Sanchez C, Veglio F, Jeunemaitre X, Corvol P, Pascoe L. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J Clin Endocrinol Metab. 1998; 83: 3996\u20134001.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-5-952"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)62105-8"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-5-892"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.37.6.1440"},{"key":"e_1_3_1_32_2","first-page":"265","volume":"1","year":"1985","unstructured":"Griffing GT, Melby JC. The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism. J Clin Hypertens. 1985; 1: 265\u2013276.","journal-title":"J Clin Hypertens"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-47-5-938"},{"key":"e_1_3_1_34_2","first-page":"115","volume":"5","year":"1991","unstructured":"Cappuccio FP, Markandu ND, Sagnella GA, Singer DR, Buckley MG, Miller MA, MacGregor GA. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens. 1991; 5: 115\u2013119.","journal-title":"J Hum Hypertens"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(92)90447-Q"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1981.241.1.C42"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00005-9"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.0000038478.59760.41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T12:51:35Z","timestamp":1715518295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.0000038478.59760.41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1161\/01.HYP.0000038478.59760.41"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.0000038478.59760.41","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]},"assertion":[{"value":"2002-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-09-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}